ALT5 Sigma Corporation

NasdaqCM:ALTS Stock Report

Market Cap: US$30.7m

ALT5 Sigma Valuation

Is ALTS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of ALTS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ALTS ($2.19) is trading below our estimate of fair value ($10.99)

Significantly Below Fair Value: ALTS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ALTS?

Key metric: As ALTS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for ALTS. This is calculated by dividing ALTS's market cap by their current revenue.
What is ALTS's PS Ratio?
PS Ratio4.3x
SalesUS$7.11m
Market CapUS$30.70m

Price to Sales Ratio vs Peers

How does ALTS's PS Ratio compare to its peers?

The above table shows the PS ratio for ALTS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average8.6x
LPCN Lipocine
3.5x16.3%US$27.5m
CARA Cara Therapeutics
1.9x46.4%US$16.7m
SLGL Sol-Gel Technologies
1.3x27.7%US$14.9m
IGXT IntelGenx Technologies
27.8xn/aUS$29.2m
ALTS ALT5 Sigma
4.3xn/aUS$30.7m

Price-To-Sales vs Peers: ALTS is good value based on its Price-To-Sales Ratio (4.3x) compared to the peer average (8.6x).

Price to Sales Ratio vs Industry

How does ALTS's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

73 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$3.94b
PRGO Perrigo
0.9x3.4%US$3.83b
BHC Bausch Health Companies
0.3x1.5%US$2.93b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
ALTS 4.3xIndustry Avg. 2.8xNo. of Companies73PS048121620+
73 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: ALTS is expensive based on its Price-To-Sales Ratio (4.3x) compared to the US Pharmaceuticals industry average (2.8x).

Price to Sales Ratio vs Fair Ratio

What is ALTS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ALTS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate ALTS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

7D

5.3%

1Y

17.0%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

7D

2.5%

1Y

15.9%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

7D

5.6%

1Y

-4.2%